Does mirtazapine cause hair loss? This is a question raised by some patients prescribed this widely used antidepressant in the UK. Mirtazapine — a noradrenergic and specific serotonergic antidepressant (NaSSA) — is licensed for depression and is generally well tolerated, but hair thinning or shedding is listed as a rare adverse effect in its Summary of Product Characteristics. Understanding how common this side effect is, why it may occur, and what steps to take if you notice changes can help patients and clinicians make informed, shared decisions about treatment.

Can Mirtazapine Cause Hair Loss?

Yes, hair loss is listed as a rare adverse effect of mirtazapine (fewer than 1 in 1,000 users), typically presenting as telogen effluvium — a diffuse, temporary shedding that usually resolves with time or after stopping the medication.

Experiencing these side effects? Our pharmacists can help you navigate them →

Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA) licensed in the UK for the treatment of depression. It is sometimes used off-label for anxiety or sleep disturbance at a clinician's discretion. It works by blocking alpha-2 adrenergic receptors and certain serotonin receptors, increasing the release of noradrenaline and serotonin in the brain. While it is generally well tolerated, some patients do report hair thinning or shedding during treatment.

Hair loss (alopecia) is listed as a rare adverse effect in mirtazapine's Summary of Product Characteristics (SmPC), meaning it is estimated to affect fewer than 1 in 1,000 users. The Medicines and Healthcare products Regulatory Agency (MHRA) Yellow Card scheme has received reports of hair loss associated with mirtazapine, though a definitive causal relationship is not always straightforward to establish, as depression itself and other concurrent factors can contribute to hair changes.

There is no well-established mechanistic explanation specific to mirtazapine and hair follicle damage. The hair loss reported is generally consistent with the pattern of telogen effluvium — a diffuse, temporary shedding that can occur with many medicines and physiological stressors — rather than permanent follicular destruction. This is the typical pattern seen with drug-induced hair loss across a range of medicines, though mirtazapine-specific evidence is limited. In most reported cases, hair regrowth occurs once the medication is stopped or the body adjusts. Patients should not discontinue mirtazapine abruptly without speaking to their GP or prescriber, as this can cause discontinuation symptoms and may worsen the underlying condition being treated.

How Common Is Hair Loss With Antidepressants in the UK?

Hair loss is uncommon across antidepressants as a class, but has been reported with mirtazapine, SSRIs, and venlafaxine via MHRA Yellow Card data; true prevalence is difficult to quantify due to multifactorial causes and underreporting.

Not sure if this is normal? Chat with one of our pharmacists →

Hair loss associated with antidepressant use is considered uncommon across the drug class as a whole, but it is not unique to mirtazapine. Several antidepressants — including selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine and sertraline, as well as other agents like venlafaxine — have been associated with hair thinning in post-marketing surveillance data and patient reports submitted to the MHRA.

In the UK, the true prevalence is difficult to quantify precisely because:

• Hair loss is often multifactorial, involving nutritional deficiencies, thyroid dysfunction, hormonal changes, or stress

• Patients may not report hair changes to their prescriber

• Depression itself is associated with physiological changes that can affect hair cycling

Post-marketing reports of antidepressant-associated alopecia are available through the MHRA Yellow Card Interactive Drug Analysis Profiles (iDAP) for individual medicines including mirtazapine and SSRIs. These reports confirm that such events are recorded in real-world practice, though they reflect spontaneous reporting and cannot be used to calculate precise incidence rates. Antidepressant-associated hair loss is generally considered to be underreported relative to actual occurrence. Antidepressants remain among the most frequently dispensed drug classes in England, as reflected in NHS Business Services Authority Prescription Cost Analysis data, meaning even rare adverse effects may affect a meaningful number of individuals in absolute terms.

For the majority of patients taking mirtazapine, hair loss will not be a significant concern. It is worth noting that drug-related shedding may coincide with or unmask an underlying tendency towards pattern hair loss, rather than directly causing it. Awareness of this potential side effect allows patients and clinicians to monitor proactively rather than reactively.

Why Some Medicines Affect Hair Growth

Most drug-induced hair loss occurs via telogen effluvium, where medications push follicles prematurely into the resting phase, causing diffuse shedding two to four months after the triggering event; this is generally reversible.

To understand why medications like mirtazapine might contribute to hair loss, it helps to appreciate the normal hair growth cycle. Hair follicles cycle through three phases: anagen (active growth), catagen (transition), and telogen (resting/shedding). Disruption to this cycle — whether from illness, nutritional deficiency, hormonal shifts, or certain drugs — can push a disproportionate number of follicles into the telogen phase simultaneously, resulting in noticeable shedding typically two to four months after the triggering event, as described in guidance from the British Association of Dermatologists (BAD) and the Primary Care Dermatology Society (PCDS).

This pattern, known as telogen effluvium, is the most common drug-induced hair loss mechanism. It is generally diffuse (affecting the whole scalp rather than patchy areas) and reversible. A second, less common mechanism is anagen effluvium, where actively growing hairs are damaged — this is more typically associated with chemotherapy agents and is not considered relevant to mirtazapine.

The precise reason why mirtazapine may occasionally be associated with telogen effluvium is not established. Several hypotheses have been proposed in the scientific literature, including possible effects of altered neurotransmitter signalling on peripheral receptors expressed in hair follicles, but these remain speculative and are not specific to mirtazapine. They should be understood as hypotheses rather than confirmed mechanisms.

It is also important to recognise that the stress of depression itself is a well-recognised cause of telogen effluvium, meaning that hair loss noticed shortly after starting an antidepressant may predate the medication rather than result from it. Careful timeline assessment by a clinician is therefore essential.

What to Do If You Notice Hair Thinning on Mirtazapine

Speak to your GP before making any medication changes; they will investigate other causes with blood tests including thyroid function, ferritin, and FBC, and assess the timeline before attributing shedding to mirtazapine.

If you notice increased hair shedding or thinning while taking mirtazapine, the first and most important step is to speak with your GP or prescribing clinician before making any changes to your medication. Stopping mirtazapine suddenly can cause discontinuation symptoms including dizziness, nausea, and rebound anxiety or low mood, and should always be done under medical supervision with a gradual tapering plan if required.

Your GP will typically want to rule out other causes of hair loss before attributing it to mirtazapine. In UK primary care, initial assessment usually includes:

• Blood tests: full blood count (FBC), thyroid function tests (TSH and free T4), and ferritin (iron stores) are the standard first-line investigations; further tests such as vitamin B12, folate, zinc, or vitamin D may be added if the clinical history or examination suggests a specific deficiency

• Assessment of recent significant stressors, weight changes, or illness

• Review of all current medications, including over-the-counter products and supplements, as other medicines (such as retinoids, anticoagulants, and antithyroid drugs) are also recognised causes of telogen effluvium

• Consideration of hormonal causes, particularly in women (e.g., polycystic ovary syndrome, post-partum changes, or perimenopause)

If you are taking high-dose biotin (vitamin B7) supplements, inform your GP before blood tests, as high-dose biotin can interfere with certain laboratory assays including thyroid function tests, as highlighted by the MHRA and NHS.

If investigations are normal and the timeline strongly suggests mirtazapine as the likely cause, your clinician may discuss whether the benefits of continuing treatment outweigh the distress caused by hair changes. In many cases, hair loss stabilises after the first few months as the body adjusts. Practical supportive measures — such as gentle hair-care practices (avoiding tight hairstyles, excessive heat styling, and chemical treatments) and ensuring adequate dietary protein and micronutrient intake — may help minimise further shedding in the interim.

Seek prompt review if hair loss is rapid, patchy, associated with scalp inflammation or scarring, or accompanied by other symptoms such as fatigue, weight change, or skin changes, as these may indicate an underlying medical condition requiring separate investigation.

Alternatives and Next Steps If Hair Loss Continues

If hair loss is confirmed as drug-related and persists, your GP or psychiatrist may consider watchful waiting, dose review, or switching to an alternative antidepressant, guided by NICE NG222 shared decision-making principles.

If hair loss persists and is felt to be directly related to mirtazapine, your GP or psychiatrist may consider whether any adjustment to your treatment is appropriate. Options may include watchful waiting if your mental health is stable and shedding appears to be settling, dose review, or switching to an alternative antidepressant. This decision must always be balanced carefully against the risk of destabilising a mental health condition that is responding well to current treatment. NICE guideline NG222 (Depression in adults: treatment and management, 2022) emphasises shared decision-making in antidepressant prescribing, taking into account the patient's preferences, previous treatment history, and tolerability profile.

Licensed alternative antidepressants that may be considered include:

• SSRIs (e.g., sertraline, escitalopram) — recommended as first-line options per NICE NG222, though hair loss has also been reported with this class

• SNRIs (e.g., venlafaxine, duloxetine) — may be considered where anxiety is a prominent feature

• Vortioxetine — a licensed option with a different pharmacological profile, which may be suitable for some patients following shared decision-making

• Agomelatine — licensed in the UK but not routinely recommended by NICE; availability varies by local formulary, and it requires baseline and ongoing liver function monitoring

It is worth noting that no antidepressant is entirely free from the risk of hair-related side effects, and switching does not guarantee resolution. If hair loss is confirmed to be drug-related and causes significant distress, referral to a consultant dermatologist with an interest in hair disorders may be appropriate. NHS dermatology services can provide specialist assessment. Treatments such as topical minoxidil are not routinely indicated for acute telogen effluvium and should only be considered on the advice of a dermatologist.

Finally, patients are encouraged to report suspected side effects — including hair loss — via the MHRA Yellow Card scheme (available at yellowcard.mhra.gov.uk). This contributes to ongoing pharmacovigilance and helps build a clearer national picture of antidepressant tolerability in real-world practice.

Frequently Asked Questions